Files in this Data Supplement:
Fig. S1 (Sequence alignment of target regions for the E9L assay) and S2 (Sequence alignment of target regions for the A13L assay based on the vaccinia virus A13L gene, which is the variola virus A14L gene)
PDF, 225K
Supplemental methods and Tables S1A (Variola virus isolates used in validation panels), S1B (Nonvariola orthopoxviruses used in validation panels), S1C (Nonorthopoxvirus agents used in validation panels), S2A (Sequences for the primers and probes of the E9L and A13L assays), S2B (Reaction setup for initial validation of both the E9L and the A13L assays on the ABI 7700), S2C (Modified reaction setup for the E9L assay on the ABI 7900 and the A13L assay on the ABI 7500 Fast DX), S2D (Cycling conditions for initial validation on the ABI 7700 for both the E9L and the A13L assays), S2E (Modified cycling conditions on the ABI 7900 or the ABI 7500 Fast DX for the E9L or the A13L assay, respectively), S3A (Sensitivity of the A13L assay for detection of the variola virus inclusivity panel), S3B (Specificity of the A13L assay against the panel containing other orthopoxviruses and rash-causing agents), S4A (Sensitivity of the E9L assay for detection of the variola virus inclusivity panel), and S4B (Specificity of the E9L assay against the panel containing other orthopoxviruses and rash-causing agents)
PDF, 501K